Online ISSN: 3007-0244,
Print ISSN:  2410-4280
POSSIBILITIES OF USING URSODEOXYCHOLIC ACID FOR THE PREVENTION OF ATHEROSCLEROSIS AND LIVER FIBROSIS IN ROUTINE PRACTICE AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
The prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NAFLD/NASH) in the world practice is steadily increasing. NAFLD/NASH can progress to liver cirrhosis and hepatocellular carcinoma. However, most patients with NAFLD/NASH die due to cardiovascular events. It should be noted that the prevalence of NAFLD is increasing parallel to the rising cases of type 2 diabetes (T2D) and obesity. Despite the growing number of patients, therapeutic approaches remain limited. This article presents the results of using ursodeoxycholic acid (UDCA) in NAFLD/NASH. Previously, according to various sources, it was found that bile acids, which include UDCA, are the main integrators of fatty acid and triglyceride metabolism in the liver. The results of our study showed that the use of UDCA in NAFLD leads to a decrease in the activity of inflammatory processes in the liver, its steatosis, and also improves lipid metabolism and has potential anti-atherogenic properties.
Aigul M. Raissova1, Aleksandr V. Nersesov1, Dzhamilya A. Kaibullayeva1, Akzhan U. Konysbekova2, Moldir A. Ismagulova2, Saltanat S. Madenova2, Margarita A. Nefedova3, Madina A. Tatiyeva4, Lyailya K. Tashenova5, Kulpash S. Kaliaskarova6, Aliya A. Konysbekova7, Shirin B. Aliyeva8, Guzel M. Dzhakupova9, Yelena I. Lipkina10, Mariya Yu. Nadinskaya11 1 Asfendiyarov National Medical University, Almaty, Republic of Kazakhstan; 2 «National Research Institute of Cardiology and Internal Medicine» JSC, Almaty, Republic of Kazakhstan; 3 INVITRO LLC, Almaty, Republic of Kazakhstan; 4 Central Family Clinic, Almaty, Republic of Kazakhstan; 5 «Institute of Gastroenterology» LLP, Almaty, Republic of Kazakhstan; 6 National Center of Oncology and Transplantology, Astana, Republic of Kazakhstan; 7 Republican Diagnostic Center, Astana, Republic of Kazakhstan; 8 Regional Clinical Hospital, Shymkent, Republic of Kazakhstan; 9 City Advisory Diagnostic Center, Shymkent, Republic of Kazakhstan; 10 Medical Clinic "Belasu", Shymkent, Republic of Kazakhstan; 11 First Moscow State Medical University named after I.M. Sechenov, Ministry of Health of Russia (Sechenov University), Moscow, Russian Federation.
1. Маевская М.В., Надинская М.Ю., Луньков В.Д., Пирогова И.Ю., Чесноков Е.В., Кодзоева Х.Б., Ивашкин В.Т. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):22-29. https://doi.org/10.22416/1382-4376-2019-29-6-22-29 2. Нерсесов А.В., Калиаскарова К. С., Раисова А.М., Кайбуллаева Д.А., Джумабаева А.Е., Новицкая М.С., Жанкалова З.М. Характеристика амбулаторных пациентов с заболеваниями печени (хронический вирусный гепатит, стеатоз печени, заболевания печени, возникшие на фоне сахарного диабета и ожирения), получающих Эссенциале® форте Н в качестве дополнения к стандартной терапии в условиях реальной практики // Medicine (Almaty). 2016.No 9 (171). P. 35–50 3. Angulo P. Nonalcoholic fatty liver disease // N Engl J Med. 2002 Apr 18;346(16):1221-31. doi: 10.1056/NEJMra011775. PMID: 11961152. 4. Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis // Nat Clin Pract Gastroenterol Hepatol. 2006 Jun;3(6):318-28. doi: 10.1038/ncpgasthep0521. PMID: 16741551. 5. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"? // Gastroenterology. 1998 Apr;114(4):842-5. doi: 10.1016/s0016-5085(98)70599-2. PMID: 9547102. 6. Engelen L., Ferreira I., Stehouwer C.D., Boutouyrie P., Laurent S. Reference Values for Arterial Measurements Collaboration. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors // Eur Heart J. 2013 Aug;34(30):2368-80. doi: 10.1093/eurheartj/ehs380. Epub 2012 Nov 27. PMID: 23186808. 7. Kasper P., Martin A., Lang S., Kütting F., Goeser T., Demir M., Steffen H.M. NAFLD and cardiovascular diseases: a clinical review // Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7. Epub 2020 Jul 21. PMID: 32696080; PMCID: PMC8238775. 8. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin Proc. 1980 Jul;55(7):434-438. PMID: 7382552. 9. Mantovani A., Csermely A., Petracca G., Beatrice G., Corey K.E., Simon T.G., Byrne C.D., Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis // Lancet Gastroenterol Hepatol. 2021 Nov;6(11):903-913. doi: 10.1016/S2468-1253(21)00308-3. Epub 2021 Sep 21. PMID: 34555346. 10. Nadinskaia M., Maevskaya M., Ivashkin V., Kodzoeva K., Pirogova I., Chesnokov E., Nersesov A., Kaibullayeva J., Konysbekova A., Raissova A., Khamrabaeva F., Zueva E. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease // World J Gastroenterol. 2021 Mar 14;27(10):959-975. doi: 10.3748/wjg.v27.i10.959. PMID: 33776366; PMCID: PMC7968130. 11. Pais R., Giral P., Khan J.F., Rosenbaum D., Housset C., Poynard T., Ratziu V. LIDO Study Group. Fatty liver is an independent predictor of early carotid atherosclerosis // J Hepatol. 2016 Jul;65(1):95-102. doi: 10.1016/j.jhep.2016.02.023. Epub 2016 Apr 26. PMID: 27129836. 12. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference // J Hepatol. 2010 Aug;53(2):372-84. doi: 10.1016/j.jhep.2010.04.008. Epub 2010 May 7. PMID: 20494470. 13. Sokolovic D., Nikolic J., Kocic G., Jevtovic-Stoimenov T., Veljkovic A., Stojanovic M., Stanojkovic Z., Sokolovic D.M., Jelic M. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation // Drug Chem Toxicol. 2013 Apr;36(2):141-8. doi: 10.3109/01480545.2012.658919. Epub 2012 Mar 2. PMID: 22385135. 14. Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis // J Hepatol. 2016 Sep. 65(3): 589-600. doi: 10.1016/j.jhep.2016.05.013. Epub 2016 May 17. PMID: 27212244. 15. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., Friedman S.L., Diago M., Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis // Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10. PMID: 25865049. 16. Wójcik-Cichy K., Koślińska-Berkan E., Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases // Clin Exp Hepatol. 2018 Mar;4(1):1-6. doi: 10.5114/ceh.2018.73155. Epub 2018 Jan 20. PMID: 29594192; PMCID: PMC5865905. 17. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention // Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20. PMID: 28930295. References: [1-2] 1. Maevskaya M.V., Nadinskaya M.Yu., Lun'kov V.D., Pirogova I.Yu., Chesnokov E.V., Kodzoeva Kh.B., Ivashkin V.T. Vliyanie ursodezoksikholevoi kisloty na vospalenie, steatoz i fibroz pecheni i faktory aterogeneza u bol'nykh nealkogol'noi zhirovoi bolezn'yu pecheni: rezul'taty issledovaniya USPEKh [The effect of ursodeoxycholic acid on inflammation, steatosis and fibrosis of the liver and atherogenesis factors in patients with non-alcoholic fatty liver disease: results of the SUCCESS study]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2019. 29(6):22-29. https://doi.org/10.22416/1382-4376-2019-29-6-22-29 [in Russian] 2. Nersesov A.V., Kaliaskarova K. S., Raisova A.M., Kaibullaeva D.A., Dzhumabaeva A.E., Novitskaya M.S., Zhankalova Z.M. Kharakteristika ambulatornykh patsientov s zabolevaniyami pecheni (khronicheskii virusnyi gepatit, steatoz pecheni, zabolevaniya pecheni, voznikshie na fone sakharnogo diabeta i ozhireniya), poluchayushchikh Essentsiale® forte N v kachestve dopolneniya k standartnoi terapii v usloviyakh real'noi praktiki [Characteristics of outpatients with liver diseases (chronic viral hepatitis, liver steatosis, liver diseases caused by diabetes mellitus and obesity) receiving Essentiale® forte N as an addition to standard therapy in real practice]. Meditsina (Almaty) [Medicine (Almaty)]. 2016. No 9 (171). P. 35–50[in Russian]
Number of Views: 190

Key words:

Category of articles: Original articles

Bibliography link

Raisova A.M., Nersesov A.V., Kaibullaeva D.A., Konysbekova A.U., Ismagulova M.A., Madenova S.S., Nefedova M.A., Tatieva M.A., Tashenova L.K., Kaliaskarova K.S., Konysbekova A.A., Alieva Sh.B., Dzhakupova G.M., Lipkina E.I., Nadinskaya M.Yu. Possibilities of using ursodeoxycholic acid for the prevention of atherosclerosis and liver fibrosis in routine practice among patients with non-alcoholic fatty liver disease // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 4, pp. 33-41. doi 10.34689/SH.2023.25.4.004

Авторизируйтесь для отправки комментариев